ANI Pharmaceuticals (ANIP) Catches Eye: Stock Jumps 17.7%
ANI Pharmaceuticals, Inc. ANIP was a big mover last session, as the company saw its shares rise nearly 18% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 28.9% in the past one-month time frame.
The company has seen two negative estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved lower over the past few weeks, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward, to see if this recent move higher can last.
ANI Pharmaceuticals currently has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
ANI Pharmaceuticals, Inc. Price
ANI Pharmaceuticals, Inc. Price | ANI Pharmaceuticals, Inc. Quote
Another stock worth considering in the Medical - Biomedical and Genetics industry is Akari Therapeutics PLC AKTX which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ANIP going up? Or down? Predict to see what others think: Up or Down
Will You Make a Fortune on the Shift to Electric Cars?
Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.
With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.
See This Ticker Free >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
Akari Therapeutics PLC (AKTX) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
